Evaluation of procalcitonin levels in nephropathic and non- nephropathic diabetic patients

Year 2018, Volume: 10 Issue: 4, 516 - 523, 01.12.2018

Murat Dağdeviren Esin Beyan Tanyel Sema Dağdeviren Esra Çopuroğlu Yavuz Çağır Özlem Doğan Derun Taner Ertuğrul Mustafa Altay

https://doi.org/10.21601/ortadogutipdergisi.365431

Abstract

Aim: To investigate how serum
procalcitonin (PCT) levels are affected in diabetic patients with and without
nephropathy, and to determine whether PCT may be indicative of an inflammation
in these patients.

Material and Method: The study included 175 patients
[75 diabetic nephropathy (group 1), 75 non-nephropathy diabetic (group 2) and
25 non-diabetic nephropathy (group 3)], and 75 healthy volunteers. Serum and
urinary creatinine, serum high sensitive C-reactive protein (HsCRP), PCT, white
blood cell, neutrophil, HbA1c and urinary protein values were obtained from
patients and control groups. Urinary protein / creatinine ratio and eGFR were
calculated.

Results: There was no significant
difference of PCT values between groups 1, 2, 3 and control group
(0.20-0.19-0.23 and 0.19, respectively) (p>0.05). HsCRP levels of all 3
patient groups were higher than the control group (p<0.001). A negative
correlation was found between eGFR values, PCT (p<0.001; r = -0.475) and
HsCRP (p<0.001; r= -0.415) values in nephropathy patients (diabetic and
non-diabetic). Patients with diabetic nephropathy were compared to those with a
eGFR of 60 or more with those below eGFR 60. When the eGFR values were lower
than 60, the HsCRP values were higher (p<0.05); there was no difference
between the PCT values (p>0.05).

Conclusion: There was no significant
increase in PCT values of diabetic and diabetic nephropathy patients. However,
there was a negative correlation between PCT level and eGFR. This suggests that
there may be an increase in PCT values, especially in advanced chronic renal
disease, regardless of the etiology.

Keywords

Diabetes, nephropathy, procalcitonin

Nefropatisi olan ve olmayan diyabetli hastalarda prokalsitonin düzeylerinin değerlendirilmesi

Abstract

Amaç: Nefropatisi olan ve olmayan
diyabetli hastalarda serum prokalsitonin (PCT) düzeylerinin nasıl etkilendiğini
araştırarak bu hastalarda PCT’nin bir enflamasyon göstergesi olup olamayacağını
belirlemektir.

Gereç
ve Yöntem:
Çalışmaya 175 hasta [75 diyabetik nefropati (grup 1), 75 nefropatisi olmayan
diyabetik (grup 2) ve 25 non-diyabetik nefropati (grup 3)]  ve 75 sağlıklı gönüllü dahil edildi. Hasta ve
kontrol gruplarının serum ve üriner kreatinin, serum high sensitive C-reaktif protein
(hsCRP), PCT, beyaz küre, nötrofil, HbA1c ve üriner protein değerleri elde
edildi. Üriner protein/kreatinin oranı ve eGFR hesaplandı.

Bulgular: Grup 1, 2 ve 3 ile kontrol
grubunun PCT değerleri (sırasıyla 0,20-0,19-0,23 ve 0,19)  arasında anlamlı bir fark yoktu (p>0,05).
Her 3 hasta grubunun hsCRP düzeyleri ise kontrol grubundan yüksekti
(p<0,001). Nefropatili hastaların (diyabetik ve non-diyabetik) GFR değerleri
ile PCT (p<0,001; r = -0,475)  ve
hsCRP (p<0,001; r= -0,415) değerleri arasında negatif korelasyon saptandı.
Diyabetik nefropatili hastalarda GFR 60’ın altında olanlarla GFR 60 ve üzerinde
olanlar karşılaştırıldığında;  GFR
değerleri 60’dan düşük olanların hsCRP değerleri daha yüksek iken (p<0,05);
PCT değerleri arasında fark yoktu (p>0,05).

Sonuç: Diyabetli ve diyabetik
nefropatili hastaların PCT değerlerinde anlamlı bir artış yoktu. Ancak PCT
düzeyi ile GFR arasında negatif korelasyon mevcuttu. Bu durum özellikle ileri
evre kronik böbrek hastalığında, etiyolojik nedenden bağımsız olarak PCT
değerlerinde artış olabileceğini göstermektedir.

Keywords

Diyabet, nefropati, prokalsitonin

References

• 1. Lopes AA. End-Stage Renal Disease Due To Diabetes In Racial/Ethnic Minorities and Disadvantaged Populations Ethnicity & Disease 2009; 19: 1-51
• 2. Kurt M, Atmaca A, Gürlek A. Diyabetik nefropati. Hacettepe Tıp Dergisi 2004; 35: 12-17.
• 3. Gross JL, Azevedo MD, Canani LH, Caramori ML, Zelmanovitz T. Diabetic Nephropathy: Diagnosis, Prevention, And Treatment. Diabetes Care 2005; 28:176–188.
• 4. Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohoun C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993;341:515-518.
• 5. Becker KL, Nylén ES, White JC, Müller B, Snider RH Jr. Clinical review 167: Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J Clin Endocrinol Metab 2004;89:1512–1525.
• 6. Scire C, Cavagna L, Perotti C, Buruschi E, Caporali R, Montecucco C. Diagnostic value of procalcitonin measurement in febrile patients with systemic autoimmune diseases. Clinical and Experimental rheumatology 2006; 24: 123-128.
• 7. Okada Y, Minakami H, Tomamasa T, et al. Serum procalcitonin concentration in patients with Kawasaki disease . J Infect 2004; 48: 199-205.
• 8. Schwenger V, Sis J, Breitbart A, Andrassy K. CRP levels in autoimmune disease can be specified by measurement of procalcitonin. İnfection 1998;26:274-276.
• 9. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:16405.
• 10. Schindler R. Causes and therapy of microinflammation in renal failure. Nephrol Dial Transplant. 2004;19:34-40.
• 11. Abbasi A, Corpeleijn E, Postmus D, et al. Plasma procalcitonin is associated with obesity, insulin resistance, and the metabolic syndrome. J Clin Endocrinol Metab 2010;95:26–31
• 12. Abbasi A, Corpeleijn E, Postmus D, et al. Plasma procalcitonin and risk of type 2 diabetes in the general population. Diabetologia. 2011;54:2463-2465
• 13. Aksu NM, Aksoy DY, Akkaş M, et al. 25-OH-Vitamin D and procalcitonin levels after correction of acute hyperglycemia. Med Sci Monit 2013;19:264-268.
• 14. Wan ZM, Chen WY, Lu ML, et al. Higher procalcitonin level in diabetic nephropathy patients compared with healthy volunteer. Sichuan Da Xue Xue Bao Yi Xue Ban. 2014;45:442-446.
• 15. Opatrná S, Klaboch J, Opatrný K Jr, et al. Procalcitonin levels in peritoneal dialysis patients. Perit Dial Int. 2005;25:470-472.
• 16. Steinbach G, Bölke E, Grünert A, Störck M, Orth K. Procalcitonin in patients with acute and chronic renal insufficiency. Wien Klin Wochenschr. 2004;116:849-853.
• 17. Meisner M, Schmidt J, Hüttner H, Tschaikowsky K. The natural elimination rate of procalcitonin in patients with normal and impaired renal function. Intensive Care Med. 2000;26 :212-216.
• 18. Herget-Rosenthal S, Klein T, Marggrafy G, et al. Modulation and Source of Procalcitonin in Reduced Renal Function and Renal Replacement Therapy. Scandinavian Journal of Immunology 2005;61:180-186.
• 19. Yuan G, Zhou L, Tang J, et al. Serum CRP levels are equally elevated in newly diagnosed type 2 diabetes and impaired glucose tolerance and related to adiponectin levels and insulin sensitivity. Diabetes Res Clin Pract. 2006;72:244-50.
• 20. Tbahriti HF, Meknassi D, Moussaoui R, et al. Inflammatory status in chronic renal failure: The role of homocysteinemia and pro-inflammatory cytokines. World J Nephrol. 2013;2:31-37.
• 21. Verma S, Szmitko PE, Yeh ET. C-reactive protein: structure affects function. Circulation 2004;109:1914-1917.
• 22. Shokouhi B, Bookani KR, Ghasemi H, Khalouei M, Rezaei NJ, Samani SM. Diagnostic and prognostic performances of serum procalcitonin in patients with blood stream infections: A parallel, case-control study comprising adults and elderly. Rev Assoc Med Bras (1992). 2017;63:521-526.